NasdaqGS:INCYBiotechs
Incyte (INCY): Reassessing Valuation After Breakthrough Therapy Status and Positive INCA033989 Phase 1 Data
Incyte (INCY) just put its INCA033989 program firmly on the radar, with Phase 1 myelofibrosis data showing meaningful responses and the FDA granting Breakthrough Therapy status in essential thrombocythemia, sharpening the stock’s long term narrative.
See our latest analysis for Incyte.
Investors are already leaning into this story, with the share price up 17.6% over the past 90 days and a 41.9% year to date share price return. The 1 year total shareholder return of 41.3% suggests momentum is...